Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy

Gene Therapy

Volumn 13, Issue 13, 2006, Pages 1052-1056

  Mitrofanova, E ^a   Unfer, R ^a   Vahanian, N ^a   Link, C ^a,b  

^a Iowa Cancer Research Foundation   (United States)

^b IOWA STATE UNIVERSITY   (United States)

Author keywords

Adenovirus; Cancer research; Sodium iodide symporter

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; IODINE 123; IODINE 125; IODINE 131; SODIUM IODIDE SYMPORTER;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; DRUG UPTAKE; GENE TARGETING; GENE THERAPY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CARCINOMA; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RATS; SPHEROIDS, CELLULAR; SYMPORTERS; THYROID NEOPLASMS; TRANSDUCTION, GENETIC; TRANSGENES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 33745224369     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302758     Document Type: Article

References (27)

1. Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484-3492.
2. Cho J-Y. A transporter gene (Sodium Iodide Symporter) for dual purposes in gene therapy: Imaging and therapy. Curr Gene Ther 2002; 2: 393-402.
3. 131I) therapy for thyroid carcinoma. JAMA 2000; 283: 2272-2274.
4. Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation. Am J Clin Oncol 1998; 21: 77-81.
5. 131I therapy for extended differentiated carcinoma of the thyroid gland. Auris Nasus Larynx 1985; 12 (Suppl 2): S67-S71.
6. Wartofsky L, Sherman SI, Gopal J, Slumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular cancer. J Clin Endocrinol Metab 1998; 83: 4195-4203.
7. Levy O, Dai G, Riedel C, Ginter CS, Paul EM, Lebowitz AN et al. Characterization of the thyroid Na+/I- symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci USA 1997; 94: 5568-5573.
8. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: Impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000; 80: 1083-1105.
9. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M et al. The sodium/iodide symporter (NIS): Characterization, regulation, and medical significance. Endocr Rev 2003; 24: 48-77.
10. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458-460.
11. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996; 226: 339-345.
12. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium iodide symporter gene. Cancer Res 1999; 59: 661-668.
13. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE et al. Prostate-specific antigen (PSA) promoter driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999; 59: 2136-2141.
14. - symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Therapy 2000; 7: 740-749.
15. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 2001; 8: 1524-1531.
16. Mitrofanova E, Unfer R, Vahanian N, Daniels W, Roberson E, Seregina T et al. Rat Sodium Iodide Symporter (rNIS) for radioiodide therapy of cancer. Clin Cancer Res 2004; 10: 6969-6976.
17. Faivre J, Clerc J, Gerolami R, Herve J, Longuet M, Liu B et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res 2004; 64: 8045-8051.
18. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004; 9: 436-442.
19. Heltemes LM, Hagan CR, Mitrofanova EE, Panchal RG, Guo J, Link CJ. The rat sodium iodide symporter gene permits more effective radioisotope concentration than human gene in human and rodent cancer cells. Cancer Gene Ther 2003; 10: 14-22.
20. Mitrofanova E, Unfer R, Vahanian N, Kane S, Carvour M, Link C. Effective growth arrest of a human colon cancer in mice using rNIS and radioiodine therapy. Human Gene Therapy 2005; 16: 1333-1337.
21. Mitrofanova E, Hagan C, Qi J, Seregina T, Link CJ. Sodium iodide symporter/radioactive iodine system has more efficient antitumor effect in three-dimensional structure. Anticancer Res 2003; 23: 2397-2404.
22. Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ. Genetically targeted radiotherapy for multiple myeloma. Blood 2003; 102: 489-496.
23. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000; 6: 871-878.
24. - Symporter of the rat. Clin Immunol Immunopath 1998; 89: 271-278.
25. Gaut AW, Niu G, Krager KJ, Graham MM, Trask DK, Domann FE. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS). Head Neck 2004; 26: 265-271.
26. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20: 557-566.
27. Valicenti RK, Bissonette EA, Chen C, Theodorescu D. Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy. J Urol 2002; 168: 2499-2504.